Skip to main content
SpringerLink
Log in

New long-acting androgens

  • Topic Paper
  • Published:
World Journal of Urology Aims and scope Submit manuscript

Abstract

Testosterone substitution treatment aims to replace physiological actions of endogenous testosterone by steadily maintaining physiological blood levels of testosterone. The underlying conditions rendering androgen replacement necessary are usually irreversible. The consequence is that almost life-long androgen replacement is required. Patient compliance with life-long androgen replacement depends on convenient pharmaceutical formulations ensuring continuity of androgen replacement. Therefore, they must be convenient in usage with a relative independence of medical services. In elderly man, safety of androgen replacement therapy is a concern but in younger subjects (below the age of 50 years) side effects of androgens are usually minimal. For them, long-acting testosterone preparations are well suited. Testosterone implants generate, depending on the dose of implants, 3–6 months of normal plasma testosterone. This method requires minor surgery. Injectable testosterone undecanoate maintains plasma testosterone in the normal range for 12 weeks.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Behre HM, Nieschlag E (1992) Testosterone buciclate (20 Aet-1) in hypogonadal men: pharmacokinetics and pharmacodynamics of the new long-acting androgen ester. J Clin Endocrinol Metab 75:1204–1210

    CAS  PubMed  Google Scholar 

  2. Behre HM, Baus S, Kliesch S, Keck C, Simoni M, Nieschlag E (1995) Potential of testosterone buciclate for male contraception: endocrine differences between responders and nonresponders. J Clin Endocrinol Metab 80:2394–2403

    CAS  PubMed  Google Scholar 

  3. Behre HM, Abshagen K, Oettel M, Hubler D, Nieschlag E (1999) Intramuscular injection of testosterone undecanoate for the treatment of male hypogonadism: phase I studies. Eur J Endocrinol 140:414–419

    CAS  PubMed  Google Scholar 

  4. Bhasin S, Swerdloff RS, Steiner B, Peterson MA, Meridores T, Galmirini M, Pandian MR, Goldberg R, Berman N (1992) A biodegradable testosterone microcapsule formulation provides uniform eugonadal levels of testosterone for 10–11 weeks in hypogonadal men. J Clin Endocrinol Metab 74:75–83

    CAS  PubMed  Google Scholar 

  5. Burris AS, Ewing LL, Sherins RJ (1988) Initial trial of slow-release testosterone microspheres in hypogonadal men. Fertil Steril 50:493–497

    CAS  PubMed  Google Scholar 

  6. Cantrill JA, Dewis P, Large DM, Newman M, Anderson DC (1984) Which testosterone replacement therapy? Clin Endocrinol (Oxf) 21:97–107

    Google Scholar 

  7. Conway AJ, Boylan LM, Howe C, Ross G, Handelsman DJ (1988) Randomized clinical trial of testosterone replacement therapy in hypogonadal men. Int J Androl 11:247–264

    CAS  PubMed  Google Scholar 

  8. Handelsman DJ, Conway AJ, Boylan LM (1990) Pharmacokinetics and pharmacodynamics of testosterone pellets in man. J Clin Endocrinol Metab 71:216–222

    CAS  PubMed  Google Scholar 

  9. Handelsman DJ, Mackey MA, Howe C, Turner L, Conway AJ (1997) An analysis of testosterone implants for androgen replacement therapy. Clin Endocrinol (Oxf) 47:311–316

    Google Scholar 

  10. Jockenhovel F, Vogel E, Kreutzer M, Reinhardt W, Lederbogen S, Reinwein D (1996) Pharmacokinetics and pharmacodynamics of subcutaneous testosterone implants in hypogonadal men. Clin Endocrinol (Oxf) 45:61–71

    Google Scholar 

  11. Kelleher S, Turner L, Howe C, Conway AJ, Handelsman DJ (1999) Extrusion of testosterone pellets: a randomized controlled clinical study. Clin Endocrinol (Oxf) 51:469–471

    Google Scholar 

  12. Kelleher S, Conway AJ, Handelsman DJ (2001) Influence of implantation site and track geometry on the extrusion rate and pharmacology of testosterone implants. Clin Endocrinol (Oxf) 55:531–536

    Google Scholar 

  13. Kelleher S, Conway AJ, Handelsman DJ (2002) A randomised controlled clinical trial of antibiotic impregnation of testosterone pellet implants to reduce extrusion rate. Eur J Endocrinol 146:513–518

    CAS  PubMed  Google Scholar 

  14. Mackey MA, Conway AJ, Handelsman DJ (1995) Tolerability of intramuscular injections of testosterone ester in oil vehicle. Hum Reprod 10:862–865

    CAS  PubMed  Google Scholar 

  15. Matsumoto AM (1994) Hormonal therapy of male hypogonadism. Endocrinol Metab Clin North Am 23:857–875

    CAS  PubMed  Google Scholar 

  16. Nieschlag E (1996) Testosterone replacement therapy: something old, something new. Clin Endocrinol (Oxf) 45:261–262

    Google Scholar 

  17. Nieschlag E, Behre HM (1998) Comparative pharmacokinetics of testosterone esters. In: Nieschlag E, Behre HM (eds) Testosterone: action, deficiency, substitution. Springer, Berlin, Heidelberg, New York, pp 294–328

  18. Nieschlag E, Wang C, Handelsman DJ, Swerdloff RS, Wu FC, Einer-Jensen N, Waites G (1992) Guidelines for the use of androgens. Special Programme of Research, Development and Research Training in Human Reproduction of the World Health Organisation. World Health Organisation, Geneva

  19. Nieschlag E, Buchter D, von Eckardstein S, Abshagen K, Simoni M, Behre HM (1999) Repeated intramuscular injections of testosterone undecanoate for substitution therapy in hypogonadal men. Clin Endocrinol (Oxf) 51:757–763

    Google Scholar 

  20. Plymate S (1994) Hypogonadism. Endocrinol Metab Clin North Am 23:749–772

    CAS  PubMed  Google Scholar 

  21. Schulte-Beerbuhl M, Nieschlag E (1980) Comparison of testosterone, dihydrotestosterone, luteinizing hormone, and follicle-stimulating hormone in serum after injection of testosterone enanthate of testosterone cypionate. Fertil Steril 33:201–203

    CAS  PubMed  Google Scholar 

  22. Schurmeyer T, Nieschlag E (1984) Comparative pharmacokinetics of testosterone enanthate and testosterone cyclohexanecarboxylate as assessed by serum and salivary testosterone levels in normal men. Int J Androl 7:181–187

    CAS  PubMed  Google Scholar 

  23. Seftel A (2002) Treatment of male hypogonadism with testosterone undecanoate injected at extended intervals of 12 weeks: a phase II study. J Urol 168:2315–2316

    Google Scholar 

  24. Snyder PJ, Lawrence DA (1980) Treatment of male hypogonadism with testosterone enanthate. J Clin Endocrinol Metab 51:1335–1339

    CAS  PubMed  Google Scholar 

  25. Sokol RZ, Palacios A, Campfield LA, Saul C, Swerdloff RS (1982) Comparison of the kinetics of injectable testosterone in eugonadal and hypogonadal men. Fertil Steril 37:425–430

    CAS  PubMed  Google Scholar 

  26. Tschop M, Behre HM, Nieschlag E, Dressendorfer RA, Strasburger CJ (1998) A time-resolved fluorescence immunoassay for the measurement of testosterone in saliva: monitoring of testosterone replacement therapy with testosterone buciclate. Clin Chem Lab Med 36:223–230

    CAS  PubMed  Google Scholar 

  27. von Eckardstein S, Nieschlag E (2002) Treatment of male hypogonadism with testosterone undecanoate injected at extended intervals of 12 weeks: a phase II study. J Androl 23:419–425

    PubMed  Google Scholar 

  28. Wang LZ (1991) The therapeutic effect of domestically produced testosterone undecanoate in Klinefelter’s syndrome. New Drugs Market 8:28–32

    CAS  Google Scholar 

  29. Zacharin MR, Warne GL (1997) Treatment of hypogonadal adolescent boys with long acting subcutaneous testosterone pellets. Arch Dis Child 76:495–499

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Endocrinology, Section of Andrology, VU University Medical Center, P.O. Box 7057, 1007 MB, Amsterdam, The Netherlands

    Louis J. Gooren

Authors
  1. Louis J. Gooren
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Louis J. Gooren.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Gooren, L.J. New long-acting androgens. World J Urol 21, 306–310 (2003). https://doi.org/10.1007/s00345-003-0364-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00345-003-0364-x

Keywords

Search

Navigation